Inozyme Company
Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism. The company's enzyme replacement therapy provides the treatment of Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), enabling patients to treat diseases characterized by mineral imbalances in the body.
Investors
Headquarters:
Boston, Massachusetts, United States
Industry:
Gene therapy
Employee Number:
11-50
Estimated Revenue:
$10M to $50M
Investors Number:
9
Funding Status:
IPO
Technology:
Data-driven Technologies
Last Funding Type:
Series A
Founded Date:
2016-01-01
Total Funding:
150099989